ISRG — Intuitive Surgical, Inc.

Summary of ISRG Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q4 revenue grew 19% year-over-year to $2.87 billion, with full-year revenue at $10.1 billion, a 21% increase.
• Pro Forma EPS: Increased by 22% to $2.53 per share for Q4, marking the third consecutive year of over 20% growth.
• Operating Margin: Pro forma operating margin remained stable at 37%, impacted by tariffs and increased operating expenses.
• Free Cash Flow: Rose significantly to $2.5 billion from $1.3 billion in 2024.
• Total Procedures: Grew 19% in 2025, with Q4 procedures up 18%. Da Vinci procedures increased by 17% and Ion procedures by 44%.
• Installed Base: Da Vinci systems increased by 12% to over 11,100 systems; Ion systems grew by 24% to nearly 1,000.

2. Strategic Updates and Business Highlights

• Product Launches: Continued rollout of da Vinci 5, with 870 systems placed in 2025. The company also introduced refurbished da Vinci Xi systems and expanded its single-port platform.
• International Growth: Strong growth in international markets, with procedures outside the U.S. accounting for 35% of total procedures.
• Digital Tools: Launched My Intuitive+, a digital subscription package aimed at enhancing surgical performance and collaboration.
• Clinical Advancements: Received FDA clearance for cardiac procedures using non-Force Feedback instruments, with plans for a measured rollout.

3. Forward Guidance and Outlook

• 2026 Procedure Growth: Anticipated da Vinci procedure growth of 13% to 15%, driven by general surgery and international markets.
• Gross Margin: Expected to range between 67% and 68% of net revenue, with tariff impacts factored in.
• Operating Expenses: Forecasted growth of 11% to 15% due to increased R&D and operational costs.
• Tax Rate: Projected pro forma income tax rate of 22% to 23%.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Increased competition in China, with local suppliers gaining market share and impacting pricing.
• Regulatory and Economic Headwinds: Potential impacts from changes in U.S. healthcare policies (ACA premium subsidies, Medicaid funding) and capital pressures in Europe and Japan.
• Utilization Concerns: Uncertainty regarding future utilization rates in ASCs and potential downward pressure on average selling prices due to refurbished systems and competitive pricing.

5. Notable Q&A Insights

• Cardiac Surgery: Management discussed the strategic importance of entering the cardiac surgery market and the development of training pathways for surgeons.
• Ambulatory Surgery Centers (ASCs): Emphasis on expanding into ASCs, focusing on high-volume, lower-acuity procedures, and the need for reliable technology and training.
• Advanced Imaging: Discussion on integrating advanced imaging features into the robotic ecosystem, with potential new revenue streams from these innovations.
• Market Dynamics: Management acknowledged the challenges in Japan and the U.K. due to budget constraints and the impact of local competition in China on their market position.

Overall, ISRG reported strong financial performance in 2025, with robust growth in procedures and revenue, while also outlining strategic initiatives for future growth amidst competitive and regulatory challenges.